Stomach Cancer Treatment Market Share Analysis Report, 2024-2033
The global stomach cancer treatment market size was exhibited at USD 3.86 billion in 2023 and is projected to hit around USD 13.22 billion by 2033, growing at a CAGR of 13.1% during the forecast period of 2024 to 2033.
Key Takeaways:
Stomach Cancer Treatment Market Report Scope
| Report Coverage | Details |
| Market Size in 2024 | USD 3.86 Billion |
| Market Size by 2033 | USD 13.22 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 13.1% |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Segments Covered | Treatment Type, Disease Indication, Route Of Administration, Drug Class, Distribution Channel, Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Scope | North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
| Key Companies Profiled | Novartis AG; Pfizer, Inc.; Mylan N.V.; F. Hoffmann La Roche Ltd.; Eli Lilly and Company; Merck & Co., Inc.; Teva Pharmaceutical Industries Ltd.; Celltrion Healthcare Co., Ltd; Samsung Bioepis; Bristol Myers Squibb Company |
Gastric cancer is one of the leading causes of cancer-related deaths and the fifth most common malignancy worldwide. According to Globocan, around 1.1 million new cases of the disease were diagnosed worldwide in 2023. The increase in disease burden and approval of pipeline candidates are anticipated to propel the growth of the market during the forecast period.
COVID-19 had a detrimental impact on cancer care. According to the National Center for Biotechnology Information (NCBI), the COVID-19 pandemic led to delays in diagnosis. Most hospitals and centers de-prioritized non-COVID-19 treatments during the initial phases of the pandemic. For instance, hospitalization for chemotherapy declined by 60% in England in the second and third quarters of 2023. However, increased adoption of recently launched products such as Enhertu and Opdivo in several countries and increased diagnosis rate beyond the COVID-19 pandemic are anticipated to fuel market growth.
Lifestyle changes such as smoking and alcoholism, an increase in obesity, and an increasing prevalence of gastroesophageal reflux disease all act as risk factors for gastric cancer. The incidence of the disease is the highest in the Asia Pacific, followed by Europe.
Targeted drugs such as Herceptin and Cyramza are frequently used for treating gastric cancer in developed countries such as the U.S., whereas chemotherapy is still the standard of care in developing countries such as China and India. There are few agents approved for treating advanced metastatic stages of the disease. However, the approval of PD-1 inhibitors such as Opdivo and Keytruda is expected to change the management of advanced metastatic stages of the disease.
The approval of new targeted and immunotherapy drugs is expected to fuel the market growth during the forecast period. For instance, in April 2023, the U.S. FDA approved Opdivo (nivolumab) for the initial treatment of patients with metastatic or advanced GC/GEJC. Similarly, in January 2023, the U.S. FDA approved Enhertu, an antibody-drug conjugate product for treating HER-2-positive metastatic gastric cancers.
However, the launch of biosimilars for Herceptin is expected to restrain the market growth. Biosimilars such as Biocon/Mylan’s Ogivri were approved in December 2017 in the U.S., followed by Celltrion/Teva’s Herzuma in December 2018. In addition, Samsung Bioepis’s trastuzumab biosimilar, Ontruzant, was approved in January 2019, and Trazimera was approved in March 2019 in the U.S. As a result of the launch of biosimilars, Herceptin sales declined by 14% in 2019 and 49% in 2023 for all indications combined.
Segments Insights:
Treatment Type Insights
The chemotherapy segment held the largest revenue share of the gastric cancer therapy market at over 40.0% in 2023 due to a high prescription rate. First-line therapy for patients diagnosed in early stages is generally surgery with adjuvant chemotherapy or neoadjuvant chemotherapy. An article suggests that around 65% of patients with advanced cancers, 85% with lymph node metastases, and 40% with metastatic disease undergo surgical procedures. Chemotherapy can be given either as neoadjuvant chemotherapy or adjuvant chemotherapy to shrink the tumor or kill the cancerous cells. Based on treatment type, the market is segmented into chemotherapy, immunotherapy, and targeted therapy.
The targeted therapy segment is expected to account for the largest share of the gastric cancer drugs market by the end of the forecast period, owing to product launches, recent advancements in the field of targeted therapy, and a robust clinical pipeline. On the other hand, the patent expiry of Herceptin is restraining the growth of this segment.
The immunotherapy segment is expected to witness the fastest growth during the forecast period due to increasing product launches. For instance, in March 2023, Bristol-Myers Squibb Company’s drug for Opdivo received approval for stomach cancer treatment in China. Another key immunotherapy drug approved is Keytruda. Immunotherapy in combination with chemotherapy is generally used as a third-line or fourth-line treatment option.
Route of Administration Insights
The injectable segment dominated the gastric cancer therapy market with a revenue share of over 90.0% in 2023. Most of the chemotherapy drugs, targeted drugs, and immunotherapy drugs are available in injectable form, leading to the dominance of this segment.
The oral segment is expected to expand at the highest rate during the forecast period. In order to overcome the cumbersome IV of IV, many companies are developing oral chemotherapy agents for treatment. For instance, Ascelia Pharma is currently conducting Phase II clinical trials for the use of Oncoral (oral irinotecan) for the treatment of gastric cancer.
Drug Class Insights
The other drug classes segment accounted for the largest share of the gastric cancer drugs market of over 60.0% in 2023. Chemotherapy currently accounts for the largest share in this segment. Chemotherapy is still widely used as a first-line treatment in countries such as China and India, which have the highest prevalence of gastric cancer.
The PD-1/PD-L1 inhibitors segment is expected to expand at the fastest CAGR during the forecast period. The approval and increasing uptake of Keytruda and Opdivo for gastric cancer therapy are driving this segment. In addition to this, the NMPA approved TYVYT (sintilimab) for the treatment of gastric cancer in China in June 2023.
Distribution Channel Insights
The specialty and retail pharmacies segment dominated the gastric cancer therapy market in 2023 with a revenue share of over 65.0%. Most of the drugs used for the treatment of gastric cancer are distributed via specialty pharmacies as they have to be stored and distributed under specific conditions. For instance, in June 2023, Blueprint Medicines recently selected PANTHERx Rare Pharmacy and Biologics, by McKesson, for the distribution of its GIST treatment drug AYVAKIT. Based on the distribution channel, the market has been segmented into hospital pharmacies, specialty and retail pharmacies, and others.
The hospital pharmacies segment accounted for the second-largest share in 2023. Most patients with gastric cancer undergo inpatient administration of treatment in developing nations. This is one of the major factors fueling the growth of this segment.
Disease Indication Insights
The GC/GEJC segment held the largest revenue share of over 88.0% in 2023. The high disease burden coupled with a large number of approved products for this indication is contributing to the growth of this segment. According to Globocan, the 5-year prevalence of stomach cancer was around 1.8 million in 2023. Based on disease indication, the market is segmented into gastric cancer/gastroesophageal junction cancer (GC/GEJC) and gastrointestinal stromal tumors.
The gastrointestinal stromal tumors (GISTs) segment is estimated to witness moderate growth during the forecast period. GISTs are rare cancers and around 4,000 to 6,000 new cases are diagnosed every year in the U.S. Targeted drugs such as Ayvakit, Gleevec, Stivarga, and Qinlock are used for the treatment of GISTs.
Regional Insights
Asia Pacific dominated the gastric cancer therapy market in 2023 with a revenue share of over 58.0%. This is mainly due to the higher prevalence of gastric cancer in this region. For instance, in 2023, the number of new cases in Japan was around 138,000, and in China, it was around 479,000. In countries such as China, chemotherapy is still the most preferred treatment option; however, the presence of a strong product pipeline and the expected approval of the products will boost regional growth during the forecast period. For instance, in September 2023, AstraZeneca and Daiichi Sankyo Company dosed the first HER-2 positive gastric cancer patient in Phase II trials of Enhertuin China.
Europe is estimated to witness considerable growth during the forecast period due to increasing investments in the development of advanced treatment options and the rising target patient population. For instance, in October 2023, the European Commission approved Bristol Myers Squibb’s Opdivo for the treatment of gastrointestinal junction cancer
Some of the prominent players in the stomach cancer treatment market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the global stomach cancer treatment market.
Treatment Type
Disease Indication
Route of Administration
Drug Class
Distribution Channel
By Region
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers